| Breast implant–associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients RN Miranda, TN Aladily, HM Prince, R Kanagal-Shamanna, D De Jong, ... Journal of clinical oncology 32 (2), 114, 2014 | 442 | 2014 |
| Bacterial biofilm infection detected in breast implant–associated anaplastic large-cell lymphoma H Hu, K Johani, A Almatroudi, K Vickery, B Van Natta, ME Kadin, G Brody, ... Plastic and reconstructive surgery 137 (6), 1659-1669, 2016 | 365 | 2016 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 348 | 2021 |
| Mantle cell lymphoma CY Cheah, JF Seymour, ML Wang Journal of clinical oncology 34 (11), 1256-1269, 2016 | 301 | 2016 |
| Primary testicular lymphoma CY Cheah, A Wirth, JF Seymour Blood, The Journal of the American Society of Hematology 123 (4), 486-493, 2014 | 218 | 2014 |
| Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T … SJ Schuster, NL Bartlett, S Assouline, SS Yoon, F Bosch, LH Sehn, ... Blood 134, 6, 2019 | 201 | 2019 |
| Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, ... Annals of Oncology 26 (6), 1175-1179, 2015 | 176 | 2015 |
| Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ... The Lancet Oncology 23 (8), 1055-1065, 2022 | 172 | 2022 |
| Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial C Thieblemont, T Phillips, H Ghesquieres, CY Cheah, MR Clausen, ... Journal of Clinical Oncology 41 (12), 2238, 2023 | 156 | 2023 |
| Idelalisib in the management of lymphoma CY Cheah, NH Fowler Blood, The Journal of the American Society of Hematology 128 (3), 331-336, 2016 | 153 | 2016 |
| A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ... British journal of cancer 111 (6), 1072-1079, 2014 | 152 | 2014 |
| Primary breast lymphoma CY Cheah, BA Campbell, JF Seymour Cancer treatment reviews 40 (8), 900-908, 2014 | 147 | 2014 |
| Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib CY Cheah, K Burbury, JF Apperley, F Huguet, V Pitini, M Gardembas, ... Blood, The Journal of the American Society of Hematology 123 (23), 3574-3577, 2014 | 142 | 2014 |
| Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network CY Cheah, A George, E Giné, A Chiappella, HC Kluin-Nelemans, ... Annals of Oncology 24 (8), 2119-2123, 2013 | 137 | 2013 |
| Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, ... Journal of Clinical Oncology 39 (15), 1609, 2021 | 123 | 2021 |
| Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma TC El-Galaly, CY Cheah, MD Bendtsen, GS Nowakowski, R Kansara, ... European Journal of Cancer 93, 57-68, 2018 | 116 | 2018 |
| FDG‐PET/CT in the management of lymphomas: current status and future directions TC El‐Galaly, D Villa, LC Gormsen, J Baech, A Lo, CY Cheah Journal of internal medicine 284 (4), 358-376, 2018 | 106 | 2018 |
| Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center D Chihara, CY Cheah, JR Westin, LE Fayad, MA Rodriguez, ... British journal of haematology 172 (1), 80-88, 2016 | 106 | 2016 |
| Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma CY Cheah, LJ Nastoupil, SS Neelapu, SG Forbes, Y Oki, NH Fowler Blood, The Journal of the American Society of Hematology 125 (21), 3357-3359, 2015 | 102 | 2015 |
| Role of the tumor microenvironment in mature B-cell lymphoid malignancies NH Fowler, CY Cheah, RD Gascoyne, J Gribben, SS Neelapu, P Ghia, ... Haematologica 101 (5), 531, 2016 | 100 | 2016 |
